BeiGene begins dosing in Phase Ib trial of BGB-283 to treat solid tumors
Being conducted across multiple centers in Australia and New Zealand, the trial will determine the efficacy of a once daily oral dosing regimen for BGB-283 in solid tumors
Being conducted across multiple centers in Australia and New Zealand, the trial will determine the efficacy of a once daily oral dosing regimen for BGB-283 in solid tumors
The company’s partner, Sanofi, will re-submit a file to the Mexican health agency to seek approval of the 1mg/vial presentation of Egrifta which is currently marketed in other
The Memantine hydrochloride tablets are the generic version of Forest laboratories’ Namenda Tablets. The company has also received final approval from the US Food and Drug Administration (FDA)
NPI markets and distributes nutraceuticals, dietary supplements, skin care products and more, both in the US and international markets. Creative Medical Health chief executive officer Timothy Warbington said:
As part of the collaboration, scientists from both the organisations will work closely in integrated teams at the Crick’s centre of biomedical research in London and GSK’s global
The NDA was based on the pivotal international, randomized, double-blind, placebo controlled Phase III trial (TOURMALINE-MM1). Around 722 patients were included in the trial, which is designed to
CB-5083 is a first-in-class, oral inhibitor of p97, a major enzyme that controls various aspects of protein homeostasis. Currently, the company is evaluating CB-5083 in two Phase I
BLU-554 is indicated to treat advanced hepatocellular carcinoma (HCC) and cholangiocarcinoma, while BLU-285 is for unresectable, treatment-resistant gastrointestinal stromal tumor (GIST). The company noted that it is also
The trial showed that atezolizumab shrank tumors in people with locally advanced or metastatic urothelial bladder cancer (UBC) who had progressed on initial treatment. High amounts of Programmed
Around 66 patients will be enrolled in this open label, non-randomized Phase I trial, which is divided into a dose-escalation phase and an expansion cohort phase. The trial